
Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Tattoo Removal with Ultrafast Burst of Pulses: Phase I-II Prospective Study
32 Pages Posted: 28 Sep 2018
More...Abstract
Background: Q-Switched laser in nano- or pico-second regime are actually the gold standard for tattoo removal. Despite the selective feature, the delivered power is important and these lasers have shown their limitations in term of efficiency, pain and side effects. We propose a new approach to avoid the energy levels used today. The objective of this study was to assess the tolerance and the efficacy of a laser delivering ultrafast burst of pulses for tattoo removal.
Methods: A preclinical followed by a phase 1-2 prospective studies were performed on ex-vivo skin explants and on healthy subjects with black tattoos, respectively, using an ultrafast burst of pulses laser (35 ps, 4 MHz, 1064 nm) with cumulative fluencies of 2.5 to 50 J/cm². Efficacy was assessed on standardized pictures by two independent physicians. Pain during treatment was evaluated using a visual analogical scale. Histological examinations were performed immediately after the laser session and at two months.
Findings: In the preclinical study, the treated explants presented no clinical sign of suffering. Histological analysis showed no damage in epidermis, dermis or hypodermis. In the first in man proof-of-concept study, 10 patients from skin type II to IV were included. The fluences of 10 and 50 J/cm2 have reduced the intensity of the pigment in 6 patients with a better decrease at 50 J/cm2. The average pain ranged from 0.4 to 2.75/10 depending on the fluences. Side effects were mild and only at the highest fluencies.
Interpretation: We report here for the first time, the use of a new way to deliver the energy into the skin by emitting a burst of pulses to sum up the energy and decreasing the unwanted heating of the tissues. Our results show that such a technique provides very good tolerance and promising efficacy for removing tattoos.
Clinical Trial Number: NCT03386760
Funding Statement: This study was supported by Irisiome©, France.
Declaration of Interests: RR and RD are employees of Irisiome© company
Ethics Approval Statement: IRB status: Accepted: 60-17 (Ile de France VI); ANSM (French Agency for Medicine Security) approval: Id-RCB : 2017-A02216-47
Keywords: Picosecond Laser; Ultrafast Burst of Pulses; Nd:YAG Laser; Tattoo Removal
Suggested Citation: Suggested Citation